Pedro Barata, MD, MSc, FACP, discusses the goals of the NRG Oncology Semiannual Meeting taking place February 15-17, 2024.
The NRG Oncology Semiannual Meeting takes place from February 15 to 17, 2024, and serves as a hub where clinicians and researchers can meet and collaborate on the latest findings and practices in the oncology field.
Pedro Barata, MD, MSc, FACP, genitourinary oncology and clinical researcher, highlights NRG as "one of the most cooperative groups out there" when it comes to providing a space for oncologists to discuss questions and problems.
Here, Barata, a member of the Young Investigators Committee and Genitourinary Committee, discusses the goals and importance of the semiannual meeting.
Transcription:
0:05 | NRG, it’s one of the most important cooperative groups out there. Basically, what that means is a number of physicians and researchers get together on a regular basis and put together and try to develop concepts that ultimately will help patients. We try to answer questions that are relevant to patients, in this case diagnosed with many cancers. It’s an organization [that] has, you know, actually has the ability to get together colleagues and experts from different specialties, including radiation oncology, urology, medical, oncology, imaging, etc. Their role in helping moving science forward, you know, for the treatment of cancer, it's super, super important and has been for a long time.
0:58 | I think NRG, it's organized the way we know it for 10 years in a row, and it has been played a very important role in the management of advanced tumors, across solid tumors, but their role in in in academic research, it's fantastic.
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More
Could Triapine With Lutetium 177 Dotatate Improve Outcomes for Neuroendocrine Tumors?
December 30th 2024Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with lutetium 177 dotatate for treating well-differentiated somatostatin receptor–-positive neuroendocrine tumors.
Read More